{"doi":"10.1016/j.ctarc.2020.100210","title":"Mitochondria-targeted magnolol inhibits OXPHOS, proliferation, and tumor growth via modulation of energetics and autophagy in melanoma cells","abstract":"INTRODUCTION: Melanoma is an aggressive form of skin cancer for which there are no effective drugs for prolonged treatment. The existing kinase inhibitor antiglycolytic drugs (B-Raf serine/threonine kinase or BRAF inhibitors) are effective for a short time followed by a rapid onset of drug resistance. PRESENTATION OF CASE: Here, we show that a mitochondria-targeted analog of magnolol, Mito-magnolol (Mito-MGN), inhibits oxidative phosphorylation (OXPHOS) and proliferation of melanoma cells more potently than untargeted magnolol. Mito-MGN also inhibited tumor growth in murine melanoma xenografts. Mito-MGN decreased mitochondrial membrane potential and modulated energetic and mitophagy signaling proteins. DISCUSSION: Results indicate that Mito-MGN is significantly more potent than the FDA-approved OXPHOS inhibitor in inhibiting proliferation of melanoma cells. CONCLUSION: These findings have implications in the treatment of melanomas with enhanced OXPHOS status due to metabolic reprogramming or drug resistance.","journal":"Cancer Treatment and Research Communications","year":2020,"id":99440,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":30,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.957,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":349889,"name":"Micaël Hardy","orcid":"0000-0003-2976-7785","position":1,"is_corresponding":false},{"id":254810,"name":"Jacek Zielonka","orcid":"0000-0002-2524-0145","position":2,"is_corresponding":false},{"id":489238,"name":"Katherine M. Weh","orcid":"0000-0002-7745-5391","position":3,"is_corresponding":false},{"id":489765,"name":"Monika Zielonka","orcid":null,"position":4,"is_corresponding":false},{"id":489766,"name":"Kathleen A. Boyle","orcid":null,"position":5,"is_corresponding":false},{"id":489767,"name":"Mahmoud Abu Eid","orcid":null,"position":6,"is_corresponding":false},{"id":489239,"name":"Donna McAllister","orcid":"0000-0001-7332-1292","position":7,"is_corresponding":false},{"id":452633,"name":"Brian Bennett","orcid":"0000-0003-2688-1478","position":8,"is_corresponding":false},{"id":489240,"name":"Laura A. Kresty","orcid":"0000-0002-4745-0522","position":9,"is_corresponding":false},{"id":295006,"name":"Michael B. Dwinell","orcid":"0000-0001-5372-633X","position":10,"is_corresponding":false},{"id":254811,"name":"Balaraman Kalyanaraman","orcid":"0000-0002-9180-8296","position":11,"is_corresponding":false},{"id":349888,"name":"Gang Cheng","orcid":"0000-0002-7170-8968","position":0,"is_corresponding":true}],"reference_count":77,"raw_metadata":null,"created_at":"2026-07-18T22:37:35.547042Z","pmid":"32987287","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}